Lasa Supergenerics Q2 Results 2026: Net loss ₹2 Cr, Revenue ₹0 Cr
Q2 FY27 results statement: what the company reported on revenue, margins and capex.
- Revenue
- ₹0Cr
- −99.7% YoY
- −99.2% QoQ
- Net profit
- −₹2Cr
- Q2 FY26: −₹6 Cr
- Margin
- −900%
- −769.3 pp YoY
- −787 pp QoQ
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Lasa Supergenerics Ltd Q2 FY27 key numbers
- Revenue
- Total income for the quarter: Rs. 1.55 Lakhs, versus Rs. 306.81 Lakhs in the corresponding quarter last year.
As stated in Lasa Supergenerics Ltd's Q2 FY27 results statement · published 16 Nov 2026. Reported figures, not investment advice.
Based on Lasa Supergenerics Ltd's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.
The short version
Revenue from operations for Q2 ending Sept 30, 2026: Rs. 1.24 Lakhs, down sharply from Rs. 306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). EBITDA for Q2 FY2026: Rs. 1.8 million, down from Rs. 52.9 million in Q2 FY2025 (Year-on-Year decline of 97%).
From Lasa Supergenerics Ltd's Q2 FY27 earnings-call transcript · updated 16 Nov 2026.
How did Lasa Supergenerics' revenue grow in the September 2026 quarter?
- Revenue from operations for Q2 ending Sept 30, 2026: Rs. 1.24 Lakhs, down sharply from Rs. 306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY).
- Total income for the quarter: Rs. 1.55 Lakhs, versus Rs. 306.81 Lakhs in the corresponding quarter last year.
- Operational disruptions due to a May 2025 factory fire severely impacted production and revenue; all operations halted at primary production unit and dependent units.
- The company is exploring recovery strategies, including contract manufacturing or leasing facilities, and potential funding arrangements to restore operations.
What happened to Lasa Supergenerics' margins in Q2 FY27?
See what Lasa Supergenerics Ltd said on profitability & margins — free account, 30 seconds.
What capex is Lasa Supergenerics planning?
2 more points from Lasa Supergenerics Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Lasa Supergenerics raising money or cutting debt?
See what Lasa Supergenerics Ltd said on fundraising & capital structure — free account, 30 seconds.
How big is Lasa Supergenerics' order book?
2 more points from Lasa Supergenerics Ltd's call on order book
Create a free account to keep reading this call
Lasa Supergenerics Ltd — Quarterly revenue & net profit
Lasa Supergenerics Ltd Q2 FY27 results — key figures
| ₹ Cr | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| Revenue | 0 | 3 | -99.7% | 1 | -99.2% |
| Operating profit (EBITDA) | -0 | -4 | — | -1 | — |
| Operating margin | -900% | -130.7% | -769.3 pp | -113% | -787 pp |
| Profit before tax | -2 | -6 | — | -3 | — |
| Net profit (PAT) | -2 | -6 | — | -4 | — |
| EPS (₹) | -0.37 | -1.25 | — | -0.71 | — |
Source: Lasa Supergenerics Ltd's results filing to NSE (standalone), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹0 Cr, net loss ₹2 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →More Q2 FY27 results in Pharmaceuticals & Biotechnology
- Sun Pharmaceutical Industries Q2 FY27 results
- Divis Laboratories Q2 FY27 resultsCapex ₹1,638 Cr
- Torrent Pharmaceuticals Q2 FY27 results
- Laurus Labs Q2 FY27 results
- Zydus Lifesciences Q2 FY27 results
- Dr Reddy's Labs Q2 FY27 resultsCapex ₹186 Cr
- Cipla Q2 FY27 results
- Mankind Pharma Q2 FY27 results
All Q2 FY27 results | Pharmaceuticals & Biotechnology rankings
Continue your research
What Lasa Supergeneri's management said in earlier quarters
Earlier calls (1)
Others in Pharmaceuticals & Biotechnology this season
- Themis Medicare (Q2 FY27)
Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q
- Panacea Biotec (Q2 FY27)
September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Biofil Chemicals (Q2 FY27)
Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem
- Alpa Laboratorie (Q2 FY27)
Standalone: ₹3,097.56 lacs . Key results statement takeaways from Alpa Laboratories Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Lasa Supergenerics Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Lasa Supergenerics Ltd Q2 FY27 results?
Lasa Supergenerics reported a net loss of ₹2 Cr on revenue of ₹0 Cr (−99.7% YoY) in Q2 FY27.
What is Lasa Supergenerics Ltd share price analysis?
Lasa Supergenerics Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹20 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Lasa Supergenerics Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
